Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Delivery of Anticancer Drugs
share announcement

Delivery of Anticancer Drugs

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: closed (10 September 2023) | Viewed by 5215

Special Issue Editor

Dr. Sharon Rossiter

E-Mail Website
Guest Editor
School of Life and Medical Sciences, University of Hertfordshire, College Lane, Hatfield AL10 9AB, UK
Interests: drug discovery; pro-drugs; drug conjugates; anti-cancer drugs; antimicrobial peptides; organic synthesis; natural products
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to announce the launch of a new Special Issue of Pharmaceutics entitled “Delivery of Anticancer Drugs”.

Despite many recent advances in both small-molecule and biological therapies, there persists the challenge of maintaining drug efficacy by ensuring that the drug reaches the tumor target.

Delivery of anticancer drugs selectively and effectively to the tumor site can be challenging for a number of reasons, including the tumor microenvironment, poor localized vasculature, and barriers to drug penetration, such as the location of the tumor, cellular drug efflux mechanisms, or dense stromal tissue layers.

The Special Issue aims to highlight the latest pharmaceutical research in developing methods for effective delivery of anticancer drugs to tumors, including approaches such as drug conjugates, polymeric or biological carriers, nanoparticles, and tumor-selective prodrugs.

Dr. Sharon Rossiter
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oncology
  • cancer targets
  • drug delivery
  • drug conjugates
  • drug targeting
  • drug delivery
  • nanotechnology

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

26 pages, 4882 KiB  
Article
Micelle-Formulated Juglone Effectively Targets Pancreatic Cancer and Remodels the Tumor Microenvironment
by Vidhi M. Shah, Syed Rizvi, Alexander Smith, Motoyuki Tsuda, Madeline Krieger, Carl Pelz, Kevin MacPherson, Jenny Eng, Koei Chin, Michael W. Munks, Colin J. Daniel, Adel Al-Fatease, Galip Gürkan Yardimci, Ellen M. Langer, Jonathan R. Brody, Brett C. Sheppard, Adam WG. Alani and Rosalie C. Sears
Pharmaceutics 2023, 15(12), 2651; https://doi.org/10.3390/pharmaceutics15122651 - 21 Nov 2023
Cited by 1 | Viewed by 1120
Abstract
Pancreatic cancer remains a formidable challenge due to limited treatment options and its aggressive nature. In recent years, the naturally occurring anticancer compound juglone has emerged as a potential therapeutic candidate, showing promising results in inhibiting tumor growth and inducing cancer cell apoptosis. [...] Read more.
Pancreatic cancer remains a formidable challenge due to limited treatment options and its aggressive nature. In recent years, the naturally occurring anticancer compound juglone has emerged as a potential therapeutic candidate, showing promising results in inhibiting tumor growth and inducing cancer cell apoptosis. However, concerns over its toxicity have hampered juglone’s clinical application. To address this issue, we have explored the use of polymeric micelles as a delivery system for juglone in pancreatic cancer treatment. These micelles, formulated using Poloxamer 407 and D-α-Tocopherol polyethylene glycol 1000 succinate, offer an innovative solution to enhance juglone’s therapeutic potential while minimizing toxicity. In-vitro studies have demonstrated that micelle-formulated juglone (JM) effectively decreases proliferation and migration and increases apoptosis in pancreatic cancer cell lines. Importantly, in-vivo, JM exhibited no toxicity, allowing for increased dosing frequency compared to free drug administration. In mice, JM significantly reduced tumor growth in subcutaneous xenograft and orthotopic pancreatic cancer models. Beyond its direct antitumor effects, JM treatment also influenced the tumor microenvironment. In immunocompetent mice, JM increased immune cell infiltration and decreased stromal deposition and activation markers, suggesting an immunomodulatory role. To understand JM’s mechanism of action, we conducted RNA sequencing and subsequent differential expression analysis on tumors that were treated with JM. The administration of JM treatment reduced the expression levels of the oncogenic protein MYC, thereby emphasizing its potential as a focused, therapeutic intervention. In conclusion, the polymeric micelles-mediated delivery of juglone holds excellent promise in pancreatic cancer therapy. This approach offers improved drug delivery, reduced toxicity, and enhanced therapeutic efficacy. Full article
(This article belongs to the Special Issue Delivery of Anticancer Drugs)
►▼ Show Figures

Figure 1

22 pages, 6458 KiB  
Article
Anisotropic, Hydrogel Microparticles as pH-Responsive Drug Carriers for Oral Administration of 5-FU
by Serena P. Teora, Elada Panavaité, Mingchen Sun, Bas Kiffen and Daniela A. Wilson
Pharmaceutics 2023, 15(5), 1380; https://doi.org/10.3390/pharmaceutics15051380 - 30 Apr 2023
Cited by 1 | Viewed by 1671
Abstract
In the last 20 years, the development of stimuli-responsive drug delivery systems (DDS) has received great attention. Hydrogel microparticles represent one of the candidates with the most potential. However, if the role of the cross-linking method, polymer composition, and concentration on their performance [...] Read more.
In the last 20 years, the development of stimuli-responsive drug delivery systems (DDS) has received great attention. Hydrogel microparticles represent one of the candidates with the most potential. However, if the role of the cross-linking method, polymer composition, and concentration on their performance as DDS has been well-studied, still, a lot needs to be explained regarding the effect caused by the morphology. To investigate this, herein, we report the fabrication of PEGDA–ALMA-based microgels with spherical and asymmetric shapes for 5-fluorouracil (5-FU) on-demand loading and in vitro pH-triggered release. Due to anisotropic properties, the asymmetric particles showed an increased drug adsorption and higher pH responsiveness, which in turn led to a higher desorption efficacy at the target pH environment, making them an ideal candidate for oral administration of 5-FU in colorectal cancer. The cytotoxicity of empty spherical microgels was higher than the cytotoxicity of empty asymmetric microgels, suggesting that the gel network’s mechanical proprieties of anisotropic particles were a better three-dimensional environment for the vital functions of cells. Upon treatment with drug-loaded microgels, the HeLa cells’ viability was lower after incubation with asymmetric particles, confirming a minor release of 5-FU from spherical particles. Full article
(This article belongs to the Special Issue Delivery of Anticancer Drugs)
►▼ Show Figures

Graphical abstract

18 pages, 1467 KiB  
Article
Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model
by Laurie Freire Boullosa, Jinthe Van Loenhout, Christophe Hermans, Ho Wa Lau, Céline Merlin, Elly Marcq, Farnaz Sedigheh Takhsha, Wim Martinet, Guido R. Y. De Meyer, Filip Lardon, Evelien L. J. Smits and Christophe Deben
Pharmaceutics 2022, 14(12), 2761; https://doi.org/10.3390/pharmaceutics14122761 - 09 Dec 2022
Cited by 2 | Viewed by 1964
Abstract
The antineoplastic activity of the thioredoxin reductase 1 (TrxR) inhibitor, auranofin (AF), has already been investigated in various cancer mouse models as a single drug, or in combination with other molecules. However, there are inconsistencies in the literature on the solvent, dose and [...] Read more.
The antineoplastic activity of the thioredoxin reductase 1 (TrxR) inhibitor, auranofin (AF), has already been investigated in various cancer mouse models as a single drug, or in combination with other molecules. However, there are inconsistencies in the literature on the solvent, dose and administration route of AF treatment in vivo. Therefore, we investigated the solvent and administration route of AF in a syngeneic SB28 glioblastoma (GBM) C57BL/6J and a 344SQ non-small cell lung cancer 129S2/SvPasCrl (129) mouse model. Compared to daily intraperitoneal injections and subcutaneous delivery of AF via osmotic minipumps, oral gavage for 14 days was the most suitable administration route for high doses of AF (10–15 mg/kg) in both mouse models, showing no measurable weight loss or signs of toxicity. A solvent comprising 50% DMSO, 40% PEG300 and 10% ethanol improved the solubility of AF for oral administration in mice. In addition, we confirmed that AF was a potent TrxR inhibitor in SB28 GBM tumors at high doses. Taken together, our results and results in the literature indicate the therapeutic value of AF in several in vivo cancer models, and provide relevant information about AF’s optimal administration route and solvent in two syngeneic cancer mouse models. Full article
(This article belongs to the Special Issue Delivery of Anticancer Drugs)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop